Overview

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Agouron Pharmaceuticals

Treatments:

Efavirenz
HIV Protease Inhibitors
Indinavir
Nelfinavir
Protease Inhibitors
Reverse Transcriptase Inhibitors